Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial

Martin F Kaiser, Rachel H Phillip, Sarah R Brown, Amy Holroyd, Elsa Ferris, Ruth M de Tute, Sadie Roberts, Laura Clayton, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Richard S Houlston, Graham Jackson, Gordon Cook, Roger G Owen, Mark T Drayson, Guy Pratt, Andrew Hall, Matthew W Jenner

Open source

DOI: 10.1016/s1470-2045(26)00286-x
Published: 2026-09
Container: The Lancet Oncology
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/s1470-2045-26-00286-x,
  title = {Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial},
  author = {Martin F Kaiser and Rachel H Phillip and Sarah R Brown and Amy Holroyd and Elsa Ferris and Ruth M de Tute and Sadie Roberts and Laura Clayton and Kristian Bowles and Mamta Garg and Anand Lokare and Christina Messiou and Richard S Houlston and Graham Jackson and Gordon Cook and Roger G Owen and Mark T Drayson and Guy Pratt and Andrew Hall and Matthew W Jenner},
  year = {2026},
  journal = {The Lancet Oncology},
  doi = {10.1016/s1470-2045(26)00286-x},
  url = {https://doi.org/10.1016/s1470-2045(26)00286-x}
}

RIS

TY  - JOUR
TI  - Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial
AU  - Martin F Kaiser
AU  - Rachel H Phillip
AU  - Sarah R Brown
AU  - Amy Holroyd
AU  - Elsa Ferris
AU  - Ruth M de Tute
AU  - Sadie Roberts
AU  - Laura Clayton
AU  - Kristian Bowles
AU  - Mamta Garg
AU  - Anand Lokare
AU  - Christina Messiou
AU  - Richard S Houlston
AU  - Graham Jackson
AU  - Gordon Cook
AU  - Roger G Owen
AU  - Mark T Drayson
AU  - Guy Pratt
AU  - Andrew Hall
AU  - Matthew W Jenner
PY  - 2026
JO  - The Lancet Oncology
DO  - 10.1016/s1470-2045(26)00286-x
UR  - https://doi.org/10.1016/s1470-2045(26)00286-x
ER  -

APA

Kaiser, M. F., Phillip, R. H., Brown, S. R., Holroyd, A., Ferris, E., Tute, R. M. D., Roberts, S., Clayton, L., Bowles, K., Garg, M., Lokare, A., Messiou, C., Houlston, R. S., Jackson, G., Cook, G., Owen, R. G., Drayson, M. T., Pratt, G., Hall, A., & Jenner, M. W. (2026). Induction and extended consolidation with daratumumab, cyclophosphamide, bortezomib, lenalidomide, and dexamethasone in patients with high-risk multiple myeloma (OPTIMUM/MUKnine): 5-year follow-up of a multicentre, externally controlled, phase 2 trial. The Lancet Oncology. https://doi.org/10.1016/s1470-2045(26)00286-x

Source records

crossref · retrieved 2026-09-26T10:16:24.793Z